Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...93949596979899100101102103...858859»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Trial primary completion date:  Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=44, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
    Trial completion date, Trial primary completion date, Gene therapy:  Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=10, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Jun 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date:  Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=28, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Jan 2024 --> Jan 2025
  • ||||||||||  mirdametinib (PD-0325901) / SpringWorks Therap, Ibrance (palbociclib) / Pfizer
    Trial completion date, Combination therapy:  PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=139, Active, not recruiting, 
    Trial completion date: Jan 2024 --> Jan 2025 Trial completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Enrollment change, Trial withdrawal:  Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype (clinicaltrials.gov) -  Feb 15, 2024   
    P4,  N=0, Withdrawn, 
    N=16 --> 0 | Trial completion date: Dec 2026 --> Feb 2024 | Initiation date: Nov 2024 --> May 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Feb 2024 N=45 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Phase classification:  TEPEZZA (clinicaltrials.gov) -  Feb 15, 2024   
    P4,  N=313, Active, not recruiting, 
    Phase classification: P --> P4 Phase classification: P3b/4 --> P4
  • ||||||||||  Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin, Ilaris (canakinumab) / Novartis
    Phase classification:  Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=41, Recruiting, 
    Phase classification: P3b/4 --> P4 Phase classification: P1b/2 --> P1/2
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    New trial, Real-world evidence, Real-world:  Migraine Survey in Gulf Region (clinicaltrials.gov) -  Feb 15, 2024   
    P=N/A,  N=200, Not yet recruiting, 
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    USE OF BLINATUMOMAB TO ACHIEVE REMISSION AND CONSOLIDATION WITH HAPLOIDENTICAL TRANSPLANT WITH CYCLOPHOSPHAMIDE FOR THE TREATMENT OF CHILDREN WITH REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2808;    
    As a strategy to achieve remission was used blinatumomab a dose 5 ?g/m2 for continous infusion of 48 hours during 7 days, increasing the dose to 15 ?g/m2 during 28 days, all patients received triple intrathecal therapy with methotrexate, arabinocide and hydrocortisone, two weeks after each cycle of blinatumomab, All patients received blinatumumab cycles hospitalized, during their stay the toxicity data related to blinatumumab was evaluated every day. The use of 2 cycles of blinatumumab is an efficient and safe strategy to achieve remission in children with relapsed/refractory ALL+19, consolidation with transplant is an efficient therapy, haploidentical transplant is an easily accessible and efficient strategy to consolidate to this group of patients in middle-income countries
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
    THINK TO CHECK PREVIOUS SEROLOGIES WHEN CMV OR TOXOPLASMA SEROLOGIES ARE NEGATIVE AT TRANSPLANT (CLYDE) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2732;    
    For CMV- or toxoplasma-seronegative patients at transplant, it is important to check serology at diagnosis each time possible, especially in patients with ALL or lymphoproliferative disorders or those who received monoclonal antibodies. The serology at the diagnosis of the underlying disease should be the one taken in consideration for adapting the management of the patient after transplant
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
    THINK TO CHECK PREVIOUS SEROLOGIES WHEN CMV OR TOXOPLASMA SEROLOGIES ARE NEGATIVE AT TRANSPLANT (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2731;    
    For CMV- or toxoplasma-seronegative patients at transplant, it is important to check serology at diagnosis each time possible, especially in patients with ALL or lymphoproliferative disorders or those who received monoclonal antibodies. The serology at the diagnosis of the underlying disease should be the one taken in consideration for adapting the management of the patient after transplant
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    THE FIRST CASE OF ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AT DHARMAIS HOSPITAL  (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2657;    
    Nonetheless, heterogeneity in allo-HCT outcomes indicates that further cooperative studies and consolidation of multicenter data is required to define the group which will benefit from allo-HCT in MRD-negative CR. Filgrastim was used as mobilization agent and HSC were collected when blood CD34 level was above 20/mcl with the target of 4
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    STEM CELL MOBILIZATION EFFECTS ON HEART SIZES AND FUNCTION (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2570;    
    It is safe and feasible to Blinatumomab maintenance therapy of high risk PH negative ALL after Allo-HSCT All patients underwent hematopoietic stem cell mobilization with chemotherapy and filgrastim 10
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    SEVERE POLYAUTOIMMUNITY AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: POTENTIAL ROLE OF THE GENETIC BACKGROUND AND CHIMERISM LOSS (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2537;    
    Moreover, although genetic testing is currently ongoing, it highlights the need for searching for underlying causes responsible both for the early development of malignancies and immune dysregulation in this category of patients, as the knowledge in the field of inborn errors of immunity with immune dysregulation is rapidly expanding. Finally, the chimerism reduction observed in this patient opens interesting physiopathological and clinical perspectives.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    SEQUENTIAL KIDNEY-STEM CELL TRANSPLANTATION IN PATIENT WITH SCHIMKE IMMUNO-OSSEOUS DYSPLASIA: CASE REPORT (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2524;    
    Moreover, the good outcome of HSCT is the reason for the development of immune tolerance to kidney graft and an argument for the full withdrawal of IST. However, the optimal approach remains unclear considering limited data and potential transplant-related challenges in SIOD patients.